SEARCH

SEARCH BY CITATION

References

  • 1
    Pietrangelo A. Hereditary hemochromatosis–a new look at an old disease. N Engl J Med 2004; 350: 2383-2397.
  • 2
    Adams PC, Barton JC. Haemochromatosis. Lancet 2007; 370: 1855-1860.
  • 3
    McDonnell SM, Preston BL, Jewell SA, Barton JC, Edwards CQ, Adams PC, et al. A survey of 2,851 patients with hemochromatosis: symptoms and response to treatment. Am J Med 1999; 106: 619-624.
  • 4
    Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399-408.
  • 5
    Merryweather-Clarke AT, Pointon JJ, Jouanolle AM, Rochette J, Robson KJ. Geography of HFE C282Y and H63D mutations. Genet Test 2000; 4: 183-198.
  • 6
    Steinberg KK, Cogswell ME, Chang JC, Caudill SP, McQuillan GM, Bowman BA, et al. Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. JAMA 2001; 285: 2216-2222.
  • 7
    Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008; 358: 221-230.
  • 8
    Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005; 352: 1769-1778.
  • 9
    Whitlock EP, Garlitz BA, Harris EL, Beil TL, Smith PR. Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2006; 145: 209-223.
  • 10
    Powell LW, Dixon JL, Ramm GA, Purdie DM, Lincoln DJ, Anderson GJ, et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med 2006; 166: 294-301.
  • 11
    Morrison ED, Brandhagen DJ, Phatak PD, Barton JC, Krawitt EL, El-Serag HB, et al. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann Intern Med 2003; 138: 627-633.
  • 12
    Crawford DH, Jazwinska EC, Cullen LM, Powell LW. Expression of HLA-linked hemochromatosis in subjects homozygous or heterozygous for the C282Y mutation. Gastroenterology 1998; 114: 1003-1008.
  • 13
    Bulaj ZJ, Ajioka RS, Phillips JD, LaSalle BA, Jorde LB, Griffen LM, et al. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med 2000; 343: 1529-1535.
  • 14
    McCune CA, Ravine D, Carter K, Jackson HA, Hutton D, Hedderich J, et al. Iron loading and morbidity among relatives of HFE C282Y homozygotes identified either by population genetic testing or presenting as patients. Gut 2006; 55: 554-562.
  • 15
    U.S. Census Bureau, Population Data. 2009. Cited December 2, 2009. http://factfinder.census.gov/home/saff.
  • 16
    Delatycki MB, Allen KJ, Nisselle AE, Collins V, Metcalfe S, du Sart D, et al. Use of community genetic screening to prevent HFE-associated hereditary haemochromatosis. Lancet 2005; 366: 314-316.
  • 17
    Gurrin LC, Bertalli NA, Dalton GW, Osborne NJ, Constantine CC, McLaren CE, et al. HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity. HEPATOLOGY 2009; 50: 94-101.
  • 18
    Giles GG, English DR. The Melbourne Collaborative Cohort Study. IARC Sci Publ 2002; 156: 69-70.
  • 19
    Ritvo PG, Fischer JS, Miller D, Andrews H, Paty HW, LaRocca NG. Multiple Sclerosis Quality of Life Inventory (MSQLI): A User's Manual. New York: National Multiple Sclerosis Society; 1997.
  • 20
    Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis 1994; 18( Suppl. 1): S79-S83.
  • 21
    Gurrin LC, Osborne NJ, Constantine CC, McLaren CE, English DR, Gertig DM, et al. The natural history of serum iron indices for HFE C282Y homozygosity associated with hereditary hemochromatosis. Gastroenterology 2008; 135: 1945-1952.
  • 22
    National Health and Medical Research Council (Australia). Australian Alcohol Guidelines: Health Risks and Benefits. Canberra, Australia: NHMRC; 2001.
  • 23
    Ines LS, da Silva JA, Malcata AB, Porto AL. Arthropathy of genetic hemochromatosis: a major and distinctive manifestation of the disease. Clin Exp Rheumatol 2001; 19: 98-102.
  • 24
    Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999; 341: 718-724.
  • 25
    Andersen RV, Tybjaerg-Hansen A, Appleyard M, Birgens H, Nordestgaard BG. Hemochromatosis mutations in the general population: iron overload progression rate. Blood 2004; 103: 2914-2919.
  • 26
    Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G–> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002; 359: 211-218.
  • 27
    Allen KJ, Warner B, Delatycki MB. Clinical haemochromatosis in HFE mutation carriers. Lancet 2002; 360: 412-413; author reply 413–414.
  • 28
    McLaren GD, McLaren CE, Adams PC, Barton JC, Reboussin DM, Gordeuk VR, et al. Clinical manifestations of hemochromatosis in HFE C282Y homozygotes identified by screening. Can J Gastroenterol 2008; 22: 923-930.